Can-Fite BioPharma (NYSE:CANF) Stock Rating Upgraded by D. Boral Capital

Can-Fite BioPharma (NYSE:CANF – Get Free Report) was upgraded by investment analysts at D. Boral Capital from a “hold” rating to a “buy” rating in a note issued to investors on Wednesday. The firm presently has a $7.00 price objective on the stock. D. Boral Capital’s price target points to a potential upside of 94.44% from the stock’s previous close.

Separately, HC Wainwright set a $5.00 price objective on shares of Can-Fite BioPharma and gave the stock a “buy” rating in a research report on Tuesday. Two research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. According to MarketBeat, Can-Fite BioPharma currently has a consensus rating of “Moderate Buy” and a consensus target price of $6.00.

Get Can-Fite BioPharma alerts:

View Our Latest Research Report on Can-Fite BioPharma

Can-Fite BioPharma Trading Up 6.2%

Shares of CANF traded up $0.21 during midday trading on Wednesday, hitting $3.60. The stock had a trading volume of 58,036 shares, compared to its average volume of 809,390. Can-Fite BioPharma has a fifty-two week low of $2.83 and a fifty-two week high of $23.40. The business has a 50-day simple moving average of $3.41 and a two-hundred day simple moving average of $4.83. The firm has a market cap of $2.36 million, a P/E ratio of -2.00 and a beta of 1.09.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of CANF. Rhumbline Advisers lifted its holdings in shares of Can-Fite BioPharma by 42.4% during the 1st quarter. Rhumbline Advisers now owns 38,268 shares of the company’s stock valued at $57,000 after buying an additional 11,388 shares during the last quarter. Jane Street Group LLC acquired a new position in Can-Fite BioPharma in the fourth quarter worth approximately $41,000. Finally, Sabby Management LLC increased its holdings in Can-Fite BioPharma by 80.3% in the third quarter. Sabby Management LLC now owns 1,406,050 shares of the company’s stock worth $871,000 after buying an additional 626,306 shares during the last quarter. 21.00% of the stock is owned by institutional investors and hedge funds.

About Can-Fite BioPharma

(Get Free Report)

Can-Fite BioPharma Ltd. is a clinical-stage biopharmaceutical company headquartered in Petah Tikva, Israel, that focuses on the development of small molecule drugs for the treatment of inflammatory, oncology and liver diseases. Established in 1994, the company leverages its proprietary technology platform centered on modulating the adenosine receptor system to advance novel therapeutic candidates. Can-Fite’s research and development efforts are directed toward addressing significant unmet medical needs in autoimmune and cancer indications.

The company’s lead product candidates include piclidenoson (CF101) and namodenoson (CF102).

Read More

• Five stocks we like better than Can-Fite BioPharma
• Dream Finders Homes’ Hostile Bid Creates a Dual Squeeze Play
• Why OpenAI’s IPO Plans Could Be a Massive Win for Microsoft
• A Real Biggie Deal: Wendy’s Serves Up a Juicy Buyout Arbitrage
• Ally Financial Is Back to Basics—And Investors Are Watching

Receive News & Ratings for Can-Fite BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Can-Fite BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.